Engflag

Properazine

Quick links to important sections

Properazine

Properazine_DA

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Properazine

Quick Facts

Property Description
Active ingredient Prochlorperazine Maleate
Form Tablet, Injection, Suppository
Pharmacological class Phenothiazine Antipsychotic, Anti-emetic Agent
Common use Nausea, Vomiting, Severe Anxiety
Origin Synthetic Compound

Properazine: Identity and Composition

Properazine is a potent, synthetic compound that contains the active ingredient Prochlorperazine Maleate, which is chemically defined as a Phenothiazine agent. The structure is specifically a Piperazine derivative within the phenothiazine family, a feature that distinguishes it chemically from some other compounds in the class. As a single active ingredient medicine, it is clinically recognized to be effective in multiple delivery methods, commonly available as tablets for oral use, solutions for injection, and suppositories, prepared with appropriate pharmaceutical excipients.

Pharmacological Classification and General Purpose

The compound's classification reflects its powerful antidopaminergic action, which places it in the dual categories of a potent anti-emetic agent and a first-generation antipsychotic (a typical neuroleptic). This dual pharmacological capacity is a distinctive feature of the drug, characterized by its profound effect on the central nervous system. The drug’s general purpose is centered on controlling severe and persistent instances of nausea and vomiting, including those associated with vertigo. Its neuroleptic profile also supports its use in providing a general stabilizing influence utilized in managing specific manifestations of psychotic disorders and profound, non-psychotic anxiety conditions.

Key Features of Prochlorperazine

Prochlorperazine is uniquely characterized by its capacity to function simultaneously as a highly effective anti-sickness agent and as a stabilizing psychotropic compound, providing therapeutic benefits across both physical and neurological domains.

Regulatory References

  1. NIH MedlinePlus: Prochlorperazine

What side effects are possible with Properazine?

Possible Side Effects and Safety Information

The officially documented safety profile for Properazine (Prochlorperazine Maleate) is characterized by adverse effects primarily related to its actions on the central nervous system and cardiovascular system, as classified in regulatory documents like the FDA Prescribing Information and European SmPCs.

Frequency and System Classification

Adverse reactions are classified by frequency. Very Common effects often include sedation and somnolence. Common adverse reactions involve Extrapyramidal Symptoms (EPS), such as restlessness (akathisia), dystonia, and features resembling Parkinson's disease. Less common effects include those related to the autonomic system, such as dry mouth, constipation, and orthostatic hypotension (dizziness upon standing).

System-Organ Class Common Regulatory Findings
Nervous System Extrapyramidal Symptoms, Sedation, Seizures
Vascular/Cardiac Hypotension, Tachycardia, QTc prolongation
Blood/Lymphatic Leukopenia, Agranulocytosis (rare)

Serious Safety Considerations

Regulatory agencies document several serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), a rare but potentially fatal condition, and Tardive Dyskinesia (TD), a syndrome of involuntary movements associated with long-term exposure. The antiemetic action of Properazine may also mask the diagnosis of other underlying severe conditions, such as brain tumors or intestinal obstruction.

Population and Time-Related Safety

Older adults with dementia-related psychosis are subject to an FDA Boxed Warning due to an increased risk of mortality and cerebrovascular events. The drug is generally not recommended for children under two years of age. Time-related patterns show that sedation and hypotension are most pronounced during the initial days of therapy, while the risk of Tardive Dyskinesia increases with the duration of treatment.

Overdose and Emergency Response

The official regulatory profile for Properazine overdose is defined by the potential for severe effects on the Central Nervous System, cardiovascular system, and neuromuscular function. Overdose may present with profound central nervous system depression, ranging from severe sleepiness and confusion to the rapid loss of consciousness and a state of coma. Acute toxicity can also lead to serious seizures and extrapyramidal reactions, such as painful dystonia and involuntary muscle movements.

Regulator-documented physiological findings include severe cardiovascular instability, which can manifest as significant hypotension (low blood pressure) and life-threatening cardiac dysrhythmias (irregular heartbeat). Any suspected overdose requires immediate medical attention due to the potential for circulatory collapse and respiratory compromise. The regulatory instructions explicitly state that no specific antidote is known to reverse the effects of toxicity, meaning treatment must be exclusively symptomatic and supportive.

Procedural steps documented in the official labeling include the use of designated vasopressor agents like norepinephrine for managing persistent hypotension, and the administration of antiparkinsonism drugs to manage acute dystonic reactions. This profile necessitates immediate hospital monitoring. Special caution is warranted for pediatric patients under two years of age, for whom the medication is not generally recommended.

Therapeutic Uses of Properazine

Prochlorperazine is an established medication applied across domains where additional symptomatic support is needed, focusing on easing symptoms related to heightened physiological activity. It is commonly used when symptoms are acute, episodic, or significantly interfere with daily comfort and stability. Its primary therapeutic applications include the management of psychotic disorder manifestations, the control of severe nausea and vomiting, and short-term relief for generalized non-psychotic anxiety.

Key Therapeutic Uses and Benefits

The medicine is relevant when supportive symptom management is appropriate for symptom clusters that may become intense or disruptive. For patients, it contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

“It is commonly used when short-term symptomatic assistance is needed.”

Easing Severe Nausea and Vomiting

This domain addresses symptom clusters related to systemic imbalance or physical discomfort, such as acute, severe nausea and vomiting. Properazine contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Support for Symptoms related to physical discomfort

Management of Distressful Symptoms

This use is considered relevant across conditions characterized by periods of heightened symptoms. It is applied in scenarios where additional management of discomfort is required and supports patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Official Eligibility Rules for Properazine

The eligibility profile for Properazine (Prochlorperazine) is defined by official regulatory documents, which establish specific criteria for use and absolute prohibitions.

Category Regulatory Status
Populations Allowed Adults (18 years and older); pediatric patients 2 years of age and older and weighing mathbfge 20 lbs (9 kg).
Absolute Contraindications Comatose states; presence of large amounts of CNS depressants; hypersensitivity to any phenothiazine; blood dyscrasias; severe liver disease; or dementia-related psychosis in the elderly.
Age Restrictions Contraindicated for use in children under 2 years of age or under 20 lbs (9 kg).

Condition-Specific Restrictions

Use is contraindicated or avoided in patients with certain severe conditions, including severe cardiovascular disorders, pheochromocytoma, and bone marrow depression. Individuals with glaucoma or prostatic hypertrophy require special caution. For non-psychotic anxiety, treatment is restricted to short-term management, typically no longer than 12 weeks, as stated in regulatory labeling.

Pregnancy and Lactation Eligibility

The medicine is not generally recommended during pregnancy unless the potential benefit significantly outweighs the potential risk. Use is specifically avoided in the third trimester due to the risk of neonatal symptoms. Caution is required for nursing mothers as the drug is known to be excreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Properazine (Prochlorperazine Maleate) identifies specific combinations and conditions that affect its use and exposure. All documented interactions relate to pharmacological or pharmacokinetic alterations of the compound.

Formal Restrictions and Contraindications

Co-administration with large amounts of Central Nervous System (CNS) Depressants, including alcohol and narcotics, is formally contraindicated due to the risk of intensified and prolonged depressant effects. Similarly, combining Properazine with certain QTc-prolonging agents, such as Dronedarone or Pimozide, is prohibited due to the risk of additive cardiac electrical prolongation.

Pharmacodynamic and Metabolic Interactions

Properazine can intensify the effects of other CNS depressants (e.g., anesthetics) and anticholinergic medicines, resulting in additive effects. The antiemetic action of the drug may mask the signs of overdosage from other medicinal products. Metabolism involves the CYP2D6 and CYP3A4 enzyme systems, which is the basis for interactions with their respective inhibitors. Regarding the oral formulation, co-administration with food decreases its exposure, specifically reducing the maximum plasma concentration (Cmax) by 23% and the Area Under the Curve (AUC) by 13%.

Special Administration Requirements

A mandatory timing rule requires the discontinuation of Properazine at least 24 hours prior to the administration of Metrizamide. Furthermore, caution is advised for elderly patients and those with conditions like uncorrected hypokalemia, especially when co-administering drugs that also affect the QTc interval or blood pressure.

Mechanism of Action

Properazine (Prochlorperazine) is a phenothiazine derivative that acts as a competitive antagonist at multiple neurotransmitter receptors within the central nervous system, particularly concentrating in subcortical areas. Its primary molecular targets include the Dopamine D2 receptor and the Serotonin 5-HT2A receptor.

Properazine sterically blocks the D2 receptor, a G-protein-coupled receptor (GPCR), thereby inhibiting the downstream G i protein signaling cascade, which normally results in decreased intracellular cyclic adenosine monophosphate (cAMP) and reduced neuronal excitability. Antagonism of D2 receptors in the chemoreceptor trigger zone (CTZ) of the medulla modulates afferent signaling to the emetic center.

Additionally, the drug exhibits antagonistic affinity for Muscarinic and Histamine H1 receptors. The blockade of H1 receptors contributes to central nervous system depression. The combined antagonism of multiple receptors alters dopaminergic, serotonergic, cholinergic, and histaminergic neurotransmission, leading to system-level modulation of motor output, sensory processing, and autonomic function.

Dosage and Administration Information

This section outlines instructions for the administration and dosing of prochlorperazine (Properazine).

Route of Administration Standard Adult Dosing Rule Administration Requirements
Oral (Tablet/Capsule) 5 to 10 mg, 3 or 4 times daily (Max: 40 mg/day) Swallow whole with water; sustained-release capsules should not be crushed or chewed.
Intramuscular (IM) 5 to 10 mg, repeated every 3 to 4 hours as needed (Max: 40 mg/day) Must be administered deeply into the upper, outer quadrant of the buttock. Subcutaneous use is not advised.
Intravenous (IV) 2.5 to 10 mg per dose (Max: 10 mg single dose; 40 mg/day) Administer slowly at a rate not exceeding 5 mg per minute. The solution should not be given as a rapid IV bolus.
Rectal (Suppository) 25 mg twice daily Insert the suppository past the muscular sphincter of the rectum (approximately one inch in adults).

Age-Group and Duration Rules

  • Pediatric Use: The medication is not recommended for children under 2 years of age or those weighing less than 9 kg (20 lbs). Dosing for children over 2 years is calculated based on body weight.
  • Duration Limit: When used for the short-term treatment of non-psychotic anxiety, the total course of therapy should not exceed 12 weeks.

Recent Clinical Evidence

Evidence for Controlling Severe Nausea and Vomiting

Research examined Properazine in short-term clinical trials, often comparing it to a placebo or other medications in acute care settings. Studies monitored outcomes related to physical discomfort, tracking changes in nausea severity and the need for rescue medications over defined, brief time intervals. The evidence is limited regarding outcomes for long-term use or for research exploring chronic nausea conditions, as follow-up durations were typically very short.

Evidence for Studying Manifestations of Psychotic Disorders

Properazine was studied for its use in conditions associated with psychotic disorders, with clinical trials contributing to its classification as a first-generation antipsychotic agent. Studies primarily monitored outcomes related to changes in positive symptoms. Certainty remains low regarding the full spectrum of long-term effects. Observational studies noted that this use was associated with patterns of increased mortality in older adults with dementia-related psychosis, an observation documented across the antipsychotic class.

Evidence for Short-Term Generalized Non-Psychotic Anxiety Relief

Properazine was evaluated in short-term clinical studies, typically lasting up to four weeks, for generalized non-psychotic anxiety. Researchers monitored outcomes using validated anxiety rating scales. The results apply only to the specific populations studied, excluding anxiety linked to other physical or mental health conditions. Follow-up durations were limited (up to 12 weeks maximum permitted use), and long-term effects are not fully established.

Summary of Research Scope and Limitations

Across all indications, comparative evidence is lacking against many contemporary treatments. Research describes its observation in children (aged two years and older) and in older adult populations but data for certain groups remain insufficient. The primary limitation is that there is limited information for long-term outcomes, as the study results reflect only the specific, short-term conditions under which they were conducted.

Key Studies & References Chlorpromazine versus placebo for schizophrenia - Cochrane Database of Systematic Reviews (Representative of First-Generation Antipsychotic Class Evidence)

Frequently Asked Questions (FAQ)

Common questions about Properazine (FAQ)

Q: What should I do if I miss a dose of my oral Properazine?

If a dose is missed, official drug information suggests taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, it is typically advised to skip the missed dose and resume the regular schedule. Do not take a double dose to make up for a missed one.

Q: Is it okay to take my Properazine tablet with food?

Official regulatory data indicates that taking the oral tablet with food can reduce the amount of the drug absorbed into the bloodstream. Consultation with the prescribing healthcare professional is recommended to clarify the specific instructions for taking this medication with or without food.

Q: What are the signs of Neuroleptic Malignant Syndrome (NMS) I should watch for?

Regulatory warnings describe Neuroleptic Malignant Syndrome (NMS) as a rare, serious condition associated with this class of medication. Signs can include a very high fever (hyperpyrexia), severe muscle stiffness, changes in mental state, and evidence of autonomic instability, such as an irregular heartbeat or excessive sweating. These manifestations are considered a medical emergency.

Q: What should I do if I think I've taken too much Properazine?

If an overdose is suspected, official medical resources advise immediately seeking emergency medical assistance or contacting a poison control center. Symptoms of an overdose may include severe drowsiness, a fast or irregular heartbeat, seizures, or a loss of consciousness.

Q: What happens if I suddenly stop taking Properazine?

Stopping this medication suddenly after long-term use may cause withdrawal symptoms, such as nausea, vomiting, or dizziness. Official drug labels advise that if chronic treatment is being discontinued, the dosage reduction should occur gradually and under the supervision of a healthcare professional.

Q: Can Properazine affect my ability to drive or operate machinery?

Official warnings caution that this medication may impair mental and physical abilities due to potential side effects like dizziness, drowsiness, and blurred vision. Patients are generally advised to use caution when performing activities that require mental alertness, such as driving or operating heavy machinery.

Q: Is there any official advice on using Properazine during pregnancy or while breastfeeding?

Official drug information states that use during pregnancy is generally not recommended unless a healthcare provider determines the potential benefit significantly outweighs the potential risk. Its use is specifically avoided in the third trimester. Because the drug may pass into breast milk, caution is advised for nursing mothers.

How should Properazine be stored and disposed of?

Properazine (Prochlorperazine Maleate) must be stored and handled according to specific regulatory conditions to ensure stability and safety.

Storage Conditions

The medication must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). It requires protection from light and must be kept in a tightly closed container. As a critical safety rule, Properazine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Properazine must be disposed of properly according to local regulations. It is often recommended to use a community medicine take-back program or disposal site. The medication must not be flushed down the toilet or poured into a drain. If no take-back program is available, the product should be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Properazine found in:

A-Z Index: